Phase I trial of viral vector based personalized vaccination elicits robust neoantigen specific antitumor T cell responses.
D'Alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, Garzia I, Antonucci L, Micarelli E, Venafra V, Gogov S, Capone A, Runswick S, Martin-Liberal J, Calvo E, Moreno V, Symeonides SN, Scarselli E, Bechter O.
D'Alise AM, et al. Among authors: capone a.
Clin Cancer Res. 2024 Mar 20. doi: 10.1158/1078-0432.CCR-23-3940. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38506710